Royalty Pharma plc (MUN:RPD)
Germany
· Delayed Price · Currency is EUR 34.06
+3.65 (12.00%)
At close: Nov 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Cystic Fibrosis Franchise Revenue | 819.92M | 826.21M |
Log In |
Log In |
Log In | Upgrade
|
| Evrysdi Revenue | 213.41M | 224.43M |
Log In |
Log In |
Log In | Upgrade
|
| Trelegy Revenue | 149.91M | 146.92M |
Log In |
Log In |
Log In | Upgrade
|
| Tremfya Revenue | 149.47M | 147.14M |
Log In |
Log In |
Log In | Upgrade
|
| Tysabri Revenue | 120.29M | 124.82M |
Log In |
Log In |
Log In | Upgrade
|
| Imbruvica Revenue | - | 131.09M |
Log In |
Log In |
Log In | Upgrade
|
| Xtandi Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Promacta Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Products Revenue | 636.85M | 548.82M |
Log In |
Log In |
Log In | Upgrade
|
| Total Income from Financial Royalty Assets | 2.23B | 2.15B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue from Intangible Royalty Assets | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Royalty Income | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Royalty Income and Revenue | 119.28M | 114.15M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -213.41M | -224.43M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 2.35B | 2.26B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2016 - 2020 |
| Portfolio Receipts | 3.12B | 2.80B |
Log In |
Log In |
Log In | Upgrade
|